Kilitch Drugs (India) Limited (KILITCH.NS)
INR 317.15
(-1.14%)
INR 317.15
(-1.14%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 120.03 Million INR | 411.35% |
| 2022 | 23.47 Million INR | -77.48% |
| 2021 | 104.22 Million INR | 342.48% |
| 2020 | 23.55 Million INR | -76.08% |
| 2019 | 98.46 Million INR | 308.9% |
| 2018 | 24.08 Million INR | 182.13% |
| 2017 | -29.32 Million INR | -22.23% |
| 2016 | -23.98 Million INR | 6.34% |
| 2015 | -25.61 Million INR | 48.57% |
| 2014 | -49.8 Million INR | 88.64% |
| 2013 | -438.52 Million INR | -1391.23% |
| 2012 | -29.4 Million INR | -2.65% |
| 2011 | -28.64 Million INR | -106.58% |
| 2010 | 435.67 Million INR | 7.63% |
| 2009 | 404.79 Million INR | 14.84% |
| 2008 | 352.47 Million INR | -6.34% |
| 2007 | 376.33 Million INR | 98.24% |
| 2006 | 189.83 Million INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 FY | 120.03 Million INR | 411.35% |
| 2023 Q1 | 591.76 Million INR | 2420.84% |
| 2023 Q2 | 200.8 Million INR | -66.07% |
| 2023 Q3 | 521.01 Million INR | 159.46% |
| 2023 Q4 | 120.03 Million INR | -76.96% |
| 2022 Q4 | 23.47 Million INR | -95.68% |
| 2022 Q1 | 572.95 Million INR | 449.73% |
| 2022 Q2 | 56.55 Million INR | -90.13% |
| 2022 FY | 23.47 Million INR | -77.48% |
| 2022 Q3 | 543.7 Million INR | 861.42% |
| 2021 Q1 | 489.01 Million INR | 1976.03% |
| 2021 FY | 104.22 Million INR | 342.48% |
| 2021 Q4 | 104.22 Million INR | -78.62% |
| 2021 Q3 | 487.48 Million INR | 327.24% |
| 2021 Q2 | 114.1 Million INR | -76.67% |
| 2020 Q4 | 23.55 Million INR | -92.8% |
| 2020 FY | 23.55 Million INR | -76.08% |
| 2020 Q2 | 127 Million INR | -58.51% |
| 2020 Q1 | 306.07 Million INR | 210.84% |
| 2020 Q3 | 327.07 Million INR | 157.53% |
| 2019 FY | 98.46 Million INR | 308.9% |
| 2019 Q3 | 342.69 Million INR | 224.44% |
| 2019 Q1 | 363.56 Million INR | 1409.75% |
| 2019 Q2 | 105.62 Million INR | -70.95% |
| 2019 Q4 | 98.46 Million INR | -71.27% |
| 2018 FY | 24.08 Million INR | 182.13% |
| 2018 Q4 | 24.08 Million INR | 0.0% |
| 2018 Q1 | 350.66 Million INR | 0.0% |
| 2017 FY | -29.32 Million INR | -22.23% |
| 2016 FY | -23.98 Million INR | 6.34% |
| 2015 FY | -25.61 Million INR | 48.57% |
| 2014 Q3 | 310.08 Million INR | 2376.82% |
| 2014 Q4 | -49.8 Million INR | -116.06% |
| 2014 Q2 | -13.61 Million INR | -101.64% |
| 2014 Q1 | 831.65 Million INR | 289.65% |
| 2014 FY | -49.8 Million INR | 88.64% |
| 2013 FY | -438.52 Million INR | -1391.23% |
| 2013 Q2 | -19.63 Million INR | -101.76% |
| 2013 Q3 | 433.92 Million INR | 2310.07% |
| 2013 Q4 | -438.52 Million INR | -201.06% |
| 2013 Q1 | 1.11 Billion INR | 3889.0% |
| 2012 Q3 | 1.12 Billion INR | 632.71% |
| 2012 Q2 | -210.34 Million INR | 0.0% |
| 2012 Q4 | -29.4 Million INR | -102.62% |
| 2012 FY | -29.4 Million INR | -2.65% |
| 2011 FY | -28.64 Million INR | -106.58% |
| 2010 FY | 435.67 Million INR | 7.63% |
| 2009 FY | 404.79 Million INR | 14.84% |
| 2008 FY | 352.47 Million INR | -6.34% |
| 2007 FY | 376.33 Million INR | 98.24% |
| 2006 FY | 189.83 Million INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Sigachi Industries Limited | 859.94 Million INR | 86.041% |
| Ind-Swift Limited | 9.5 Billion INR | 98.738% |
| Bajaj HealthCare Limited | 3.29 Billion INR | 96.361% |
| Sakar Healthcare Limited | 790.93 Million INR | 84.823% |
| Aurobindo Pharma Limited | 3.69 Billion INR | 96.75% |
| Innova Captab Limited | 2.33 Billion INR | 94.856% |
| Divi's Laboratories Limited | -39.77 Billion INR | 100.302% |
| AstraZeneca Pharma India Limited | -5.01 Billion INR | 102.395% |
| Morepen Laboratories Limited | -231.17 Million INR | 151.926% |
| Mankind Pharma Limited | -1.74 Billion INR | 106.866% |
| Sequent Scientific Limited | 4.17 Billion INR | 97.127% |
| Wanbury Limited | 1.1 Billion INR | 89.145% |
| Laurus Labs Limited | 24.35 Billion INR | 99.507% |
| Nectar Lifesciences Limited | 6.15 Billion INR | 98.05% |
| Glenmark Life Sciences Limited | -2.84 Billion INR | 104.223% |
| Alembic Limited | 66.9 Million INR | -79.43% |
| Hikal Limited | 7.96 Billion INR | 98.493% |
| Alembic Pharmaceuticals Limited | 3.86 Billion INR | 96.895% |
| Neuland Laboratories Limited | -214.05 Million INR | 156.078% |
| J. B. Chemicals & Pharmaceuticals Limited | 2.82 Billion INR | 95.745% |
| Glenmark Pharmaceuticals Limited | -4.28 Billion INR | 102.801% |
| IOL Chemicals and Pharmaceuticals Limited | -1.1 Billion INR | 110.9% |
| Themis Medicare Limited | 764.96 Million INR | 84.308% |
| RPG Life Sciences Limited | -364.7 Million INR | 132.914% |
| Zydus Lifesciences Limited | 3.91 Billion INR | 96.932% |
| Lupin Limited | 19.38 Billion INR | 99.381% |
| Amrutanjan Health Care Limited | -248.79 Million INR | 148.249% |
| Wockhardt Limited | 18.27 Billion INR | 99.343% |
| Vaishali Pharma Limited | 119.13 Million INR | -0.759% |
| Aarti Pharmalabs Limited | 2.61 Billion INR | 95.404% |
| Jagsonpal Pharmaceuticals Limited | -1.38 Billion INR | 108.636% |
| Jubilant Pharmova Limited | 27.07 Billion INR | 99.557% |
| FDC Limited | -57.75 Million INR | 307.853% |
| Dr. Reddy's Laboratories Limited | 12.91 Billion INR | 99.07% |
| Eris Lifesciences Limited | 13.8 Billion INR | 99.131% |
| Venus Remedies Limited | -267.7 Million INR | 144.841% |
| ZIM Laboratories Limited | 983.6 Million INR | 87.796% |
| Bliss GVS Pharma Limited | -1.15 Billion INR | 110.368% |
| Par Drugs and Chemicals Limited | -366.53 Million INR | 132.749% |
| Caplin Point Laboratories Limited | -5.5 Billion INR | 102.179% |
| Shilpa Medicare Limited | 9.06 Billion INR | 98.676% |
| Albert David Limited | -278.36 Million INR | 143.122% |
| Ajanta Pharma Limited | -954.9 Million INR | 112.571% |
| Hester Biosciences Limited | 2.29 Billion INR | 94.76% |
| Suven Pharmaceuticals Limited | 144.97 Million INR | 17.201% |
| Solara Active Pharma Sciences Limited | 10.03 Billion INR | 98.803% |
| Gufic Biosciences Limited | 3.19 Billion INR | 96.242% |
| Windlas Biotech Limited | -273.04 Million INR | 143.964% |
| Procter & Gamble Health Limited | -2.34 Billion INR | 105.112% |
| Aarey Drugs & Pharmaceuticals Limited | 297.57 Million INR | 59.662% |
| Mangalam Drugs & Organics Limited | 975.81 Million INR | 87.699% |
| Granules India Limited | 9.28 Billion INR | 98.707% |
| Aarti Drugs Limited | 5.54 Billion INR | 97.837% |
| Bal Pharma Limited | 1.26 Billion INR | 90.5% |
| Alkem Laboratories Limited | -1.6 Billion INR | 107.459% |
| Sun Pharmaceutical Industries Limited | -72.47 Billion INR | 100.166% |
| Lincoln Pharmaceuticals Limited | -127.63 Million INR | 194.046% |
| Medicamen Biotech Limited | 160.31 Million INR | 25.124% |
| Unichem Laboratories Limited | 931.91 Million INR | 87.119% |
| Bafna Pharmaceuticals Limited | 229.93 Million INR | 47.794% |
| Biofil Chemicals and Pharmaceuticals Limited | -18.44 Million INR | 750.759% |
| Valiant Laboratories Limited | 649.9 Million INR | 81.53% |
| Orchid Pharma Limited | -1.31 Billion INR | 109.136% |
| Medico Remedies Limited | 78.67 Million INR | -52.572% |
| Ind-Swift Laboratories Limited | -4.15 Billion INR | 102.89% |
| Ipca Laboratories Limited | 11.41 Billion INR | 98.948% |
| Brooks Laboratories Limited | 49.48 Million INR | -142.577% |
| Syncom Formulations (India) Limited | 46.21 Million INR | -159.763% |
| Piramal Enterprises Limited | 491.39 Billion INR | 99.976% |
| Torrent Pharmaceuticals Limited | 31.83 Billion INR | 99.623% |
| NATCO Pharma Limited | -5.81 Billion INR | 102.064% |
| Suven Life Sciences Limited | -1.63 Billion INR | 107.352% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | 93.79% |
| Strides Pharma Science Limited | 23.25 Billion INR | 99.484% |
| Indoco Remedies Limited | 6.47 Billion INR | 98.146% |
| Alpa Laboratories Limited | 35.36 Million INR | -239.448% |
| Lasa Supergenerics Limited | 205.79 Million INR | 41.672% |
| Sun Pharma Advanced Research Company Limited | -941.8 Million INR | 112.746% |